Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2023-09-05 00:00:00 ET · period of report 2023-08-31 · accession 0001415889-23-012922 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-09-05 | 2023-08-31+ | OLMA | Harmon Cyrus | Dir | S - Sale | $10.26 | -25.0K | 998.7K | -2% | -$256.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-31 | S | D | 15,000 | $9.36 | 1,008,714 | D | — | — | (F2) The weighted average sale price for the transaction reported was $9.36, and the range of prices were between $9.22 and $9.60. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2023-09-05 | S | D | 10,000 | $11.62 | 998,714 | D | — | — | (F3) The weighted average sale price for the transaction reported was $11.62, and the range of prices were between $10.91 and $12.34. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |